Welcome to the e-CCO Library!

P526 Body mass index and response to TNF-α inhibitors in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F. Nordin1, B. Shadbolt2, K. Subramaniam1,3

Created: Thursday, 30 January 2020, 10:12 AM
P526: A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Van Linschoten, R.(1,2)*;Jansen, F.(3);Pauwels, R.(2);Smits, L.(3);Atsma, F.(4);Kievit, W.(5);de Jong, D.(3);de Vries, A.(2);Boekema, P.(6);West, R.(1);Bodelier, A.(7);Gisbertz, I.(8);Wolfhagen, F.(9);Romkens, T.(10);Lutgens, M.(11);van Bodegraven, A.(12);Oldenburg, B.(13);Pierik, M.(14);Russel, M.(15);de Boer, N.(16);Mallant-Hent, R.(17);ter Borg, P.(18);van der Meulen-de Jong, A.(19);Jansen, J.(20);Jansen, S.(21);Tan, A.(22);van der Woude, C.J.(2);Hoentjen, F.(23);
Created: Friday, 14 July 2023, 11:05 AM
P526: A prospective 52-week mucosal healing and deep remission assessment of small bowel and colonic Crohn's disease as detected by colon capsule endoscopy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Oliva S.*1, Cohen S.2, Civitelli F.1, Aloi M.1, Viola F.1, Casciani E.3, Maccioni F.4, Hassan C.5, Papoff P.6, Cucchiara S.1

Created: Wednesday, 20 February 2019, 10:36 AM
P526: Early sonographic response predicts long-term outcome in Crohn’s disease: A prospective cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Novak1*, J. Halasz1, C. Lu1, G. Kaplan1,2, C. Seow1, D. Tanyingoh2, S. Devlin1, R. Panaccione1, S. Wilson3

Created: Thursday, 21 February 2019, 9:14 AM
P526: Measurement of thiopurine metabolites concentrations after one week of treatment does not predict treatment failure in Inflammatory Bowel Disease patients
Year: 2022
Source: ECCO'22
Authors: DebenMSc, D.(1);Van Moorsel, F.(2,3);Creemers, R.(4,5);Winkens, B.(6);Bus, P.(7);Pierik, M.(5);Simsek, M.(8);De Boer, N.(8);Wong, D.(1);Van Bodegraven, A.(4,8);
Created: Friday, 11 February 2022, 3:56 PM
P526: Survey of adherence to treatment in inflammatory bowel disease: ENADEII STUDY
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

I. Alonso Abreu*1, O. Alarcón-Fernández1, M. Carrillo-Palau1, L. Ramos López1, J. P. Gisbert2, M. Chaparro2, P. Nos3, A. Jiménez Sosa4, E. Quintero Carrión1, GETECCU1

Created: Friday, 22 February 2019, 9:41 AM
P527 A review of adverse events associated with immunosuppressive treatments in inflammatory bowel disease patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D. Tassone1, N. Ding2

Created: Thursday, 30 January 2020, 10:12 AM
P527: Body image dissatisfaction is increased in inflammatory bowel disease compared with healthy matched controls but not diseased controls
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

H. Su*1, A. Chen1, S. Brown1, J. Alcantara1, D. Sim2, H. Myint1, P. Lilic1, S. Inns1,2

Created: Friday, 22 February 2019, 9:41 AM
P527: Infliximab biosimilar switching program overseen by specialist pharmacist saves money, realises investment and optimises therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

St. Clair Jones A.*1, Smith M.2

Created: Wednesday, 20 February 2019, 10:36 AM
P527: Investigating fatigue in vedolizumab-treated patients with ulcerative colitis or Crohn’s disease from a Belgian registry
Year: 2021
Source: ECCO'21 Virtual
Authors: Louis , E.(1);Muls , V.(20);Bossuyt , P.(2);Colard , A.(3);Nakad , A.(4);Baert , D.(5);Mana , F.(6);Caenepeel , P.(7);Vanden Branden , S.(8);Vermeire , S.(9);D'Heygere , F.(10);Strubbe , B.(11);Cremer , A.(12);Setakhr , V.(13);Baert , F.(14);Vijverman , A.(15);Coenegrachts , J.L.(16);Flamme , F.(17);Hantson , A.(18);Bennett , D.(19);Van Gassen , G.(18);Hantsbarger , G.(19);
Created: Wednesday, 2 June 2021, 4:12 PM
P527: Leucine-rich alpha 2 glycoprotein- A useful biomarker to discriminate mucosal healing in CRP-negative ulcerative colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Tanaka, A.(1)*;Kanmura, S.(1);Maeda, N.(1);Kuwazuru, K.(1);Komaki, F.(1);Komaki, Y.(1);Ido, A.(1);
Created: Friday, 14 July 2023, 11:05 AM
P527: Low adalimumab serum levels at Week 4 provoke immunogenicity and influence therapy outcome in anti-TNF naïve Crohn’s disease patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Verstockt1,2*, G. Moors1, S. Bian3, T. Van Stappen3, S. Tops3, V. Ballet1, G. Van Assche1,2, S. Vermeire1,2, A. Gils3, M. Ferrante1,2

Created: Thursday, 21 February 2019, 9:14 AM
P527: Telemedicine in IBD patients: results of a national survey of the Italian IBD patients’ association (AMICI Onlus)
Year: 2022
Source: ECCO'22
Authors: Costantino, A.(1,2);Caprioli, F.(1,2);Vecchi, M.(1,2);Stocco, D.(3);Aloi, M.(4);Armuzzi, A.(5);Ficari, F.(6);Manguso, F.(7);Mocci, G.(8);Orlando, A.(9); Pironi, L.(10);Radice, S.(11);Rizzello, F.(12);Tongiorgi, A.(13);Leone, S.(14);Bossa, F.(15);
Created: Friday, 11 February 2022, 3:56 PM
P528 Response to biologic therapy in operated Crohn’s disease patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A.C. Georgieva, A. Atanassova, M. Mirchev

Created: Thursday, 30 January 2020, 10:12 AM
P528: Effectiveness, Safety and Incremental Costs of Proactive Therapeutic Drug Monitoring of Infliximab in a Prospective Cohort of Inflammatory Bowel Disease Patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Zelinkova, Z.(1)*;Podmanicky, D.(2);Kadleckova, B.(1);
Created: Friday, 14 July 2023, 11:05 AM
P528: Feasibility, satisfaction and machine learning analysis of factors influencing IBD patients’ trust in the mobile application Care4today IBD
Year: 2022
Source: ECCO'22
Authors: Costantino, A.(1,2);Vecchi, M.(1,2);Stocco, D.(3);Noviello, D.(4);Conforti, F.S.(1);Maregatti, M.(4);Caprioli, F.(1,2);
Created: Friday, 11 February 2022, 3:56 PM
P528: Long-term outcome of ulcerative colitis patients responders to cyclosporine in the biological era
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bastida G.*1,2, Sargalt L.3, Garcia V.4, Mesonero F.5, Braithwaite A.M.6, Montserrat A.7, Martín M.D.8, Sicilia B.9, Olivares D.10, Vicente R.11, Rodriguez E.12, Navarro P.13, Lobaton T.3

Created: Wednesday, 20 February 2019, 10:36 AM
P528: Patients’ perspectives on switching from reference infliximab to CT-P13 biosimilar in patients with inflammatory bowel disease: A 12-month prospective observational cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Petitdidier1*, C. Gagniere1, A.L. Rentien1, J. Tannoury1, Y. Le Baleur2, F. Mesli1, I. Sobhani1, A. Amiot1

Created: Thursday, 21 February 2019, 9:14 AM
P528: Reducing intravenous monoclonal antibody observation times without compromising patient safety; a single-centre observational study.
Year: 2021
Source: ECCO'21 Virtual
Authors: Rees, F.(1);Packham, A.(1);Parmar, A.(1);Hills, E.(1);Smith, M.(1);St. Clair Jones, A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM